Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences.

BACKGROUND Methods for the development of clinical guidelines have advanced dramatically over the past 2 decades to strive for trustworthiness, transparency, user-friendliness, and rigor. The American Society of Hematology (ASH) guidelines on venous thromboembolism (VTE) have followed these advances, together with application of methodological innovations. OBJECTIVE In this article, we describe methods and methodological innovations as a model to inform future guideline enterprises by ASH and others to achieve guideline standards. Methodological innovations introduced in the development of the guidelines aim to address current challenges in guideline development. METHODS We followed ASH policy for guideline development, which is based on the Guideline International Network (GIN)-McMaster Guideline Development Checklist and current best practices. Central coordination, specialist working groups, and expert panels were established for the development of 10 VTE guidelines. Methodological guidance resources were developed to guide the process across guidelines panels. A methods advisory group guided the development and implementation of methodological innovations to address emerging challenges and needs. RESULTS The complete set of VTE guidelines will include >250 recommendations. Methodological innovations include the use of health-outcome descriptors, online voting with guideline development software, modeling of pathways for diagnostic questions, application of expert evidence, and a template manuscript for publication of ASH guidelines. These methods advance guideline development standards and have already informed other ASH guideline projects. CONCLUSIONS The development of the ASH VTE guidelines followed rigorous methods and introduced methodological innovations during guideline development, striving for the highest possible level of trustworthiness, transparency, user-friendliness, and rigor.

[1]  W. Ageno,et al.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. , 2020, Blood advances.

[2]  C. de Wolf,et al.  Development and use of health outcome descriptors: a guideline development case study , 2020, Health and Quality of Life Outcomes.

[3]  H. Schünemann,et al.  Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines. , 2020, Blood advances.

[4]  E. Akl,et al.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. , 2020, Blood advances.

[5]  S. Duffy,et al.  Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines , 2019, Annals of Internal Medicine.

[6]  F. Dentali,et al.  American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. , 2019, Blood advances.

[7]  S. Vesely,et al.  American Society of Hematology 2019 guidelines for immune thrombocytopenia. , 2019, Blood advances.

[8]  Fares Alahdab,et al.  American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. , 2019, Blood advances.

[9]  E. Akl,et al.  2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. , 2019, Blood advances.

[10]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[11]  S. Duffy,et al.  Methods for Development of the European Commission Initiative on Breast Cancer Guidelines , 2019, Annals of Internal Medicine.

[12]  A. Oxman,et al.  Distinguishing opinion from evidence in guidelines , 2019, BMJ.

[13]  S. Vesely,et al.  American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. , 2018, Blood advances.

[14]  B. Rochwerg,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. , 2018, Blood advances.

[15]  F. Dentali,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. , 2018, Blood advances.

[16]  H. Schünemann,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. , 2018, Blood advances.

[17]  G. Guyatt,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. , 2018, Blood advances.

[18]  R. Mustafa,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. , 2018, Blood advances.

[19]  Lara A. Kahale,et al.  Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. , 2018, The Cochrane database of systematic reviews.

[20]  G. Gartlehner,et al.  [GRADE: Evidence to Decision (EtD) frameworks - a systematic and transparent approach to making well informed healthcare choices. 1: Introduction]. , 2018, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[21]  Lara A. Kahale,et al.  Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2021, The Cochrane database of systematic reviews.

[22]  Lara A. Kahale,et al.  Parenteral anticoagulation in ambulatory patients with cancer. , 2017, The Cochrane database of systematic reviews.

[23]  F. Song,et al.  A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. , 2017, Annals of internal medicine.

[24]  M. Brouwers,et al.  Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp) , 2017, PLoS medicine.

[25]  Alonso Carrasco-Labra,et al.  GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. , 2017, Journal of clinical epidemiology.

[26]  Elie A Akl,et al.  [A reporting tool for practice guidelines in health care: the RIGHT statement]. , 2017, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[27]  G. Guyatt,et al.  Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. , 2016, Journal of clinical epidemiology.

[28]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[29]  G. Guyatt,et al.  When and how to update systematic reviews: consensus and checklist , 2016, British Medical Journal.

[30]  G. Guyatt,et al.  GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines , 2016, British Medical Journal.

[31]  Gordon H Guyatt,et al.  GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction , 2016, British Medical Journal.

[32]  Rachel Churchill,et al.  ROBIS: A new tool to assess risk of bias in systematic reviews was developed , 2016, Journal of clinical epidemiology.

[33]  Holger J Schünemann,et al.  Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. , 2015, Annals of internal medicine.

[34]  G. Guyatt,et al.  Guideline panels should not GRADE good practice statements. , 2015, Journal of clinical epidemiology.

[35]  M. Tirani,et al.  [Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise]. , 2015, Recenti progressi in medicina.

[36]  Lara A. Kahale,et al.  Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. , 2014, The Cochrane database of systematic reviews.

[37]  Romina Brignardello-Petersen,et al.  Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise , 2014, Canadian Medical Association Journal.

[38]  David Rind,et al.  GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. , 2013, Journal of clinical epidemiology.

[39]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[40]  Günter Ollenschläger,et al.  Guidelines International Network: Toward International Standards for Clinical Practice Guidelines , 2012, Annals of Internal Medicine.

[41]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[42]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[43]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[44]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[45]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[46]  C. Bias.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .

[47]  S. Greenfield,et al.  Clinical practice guidelines we can trust , 2011 .

[48]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[49]  Marilyn J. Field,et al.  Conflict of Interest in Medical Research, Education, and Practice , 2009 .

[50]  G. Guyatt,et al.  Do Clinical Marker States Improve Responsiveness and Construct Validity of the Standard Gamble and Feeling Thermometer: A Randomized Multi-Center Trial in Patients with Chronic Respiratory Disease , 2006, Quality of Life Research.

[51]  H. Schünemann,et al.  Measurement of agreement on health-related quality of life changes in response to respiratory rehabilitation by patients and physicians--a prospective study. , 2004, Respiratory medicine.

[52]  Gordon H Guyatt,et al.  A Randomized Multicenter Trial to Evaluate Simple Utility Elicitation Techniques in Patients With Gastroesophageal Reflux Disease , 2004, Medical care.

[53]  G. Guyatt,et al.  Methodology for guideline development for the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[54]  G. Guyatt,et al.  A Clinical Trial to Evaluate the Measurement Properties of 2 Direct Preference Instruments Administered with and without Hypothetical Marker States , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[55]  G. Palombarini.  Methodology of Guideline Development. , 2002, Neurosurgery.